Abbisko Therapeutics Co, Ltd
Clinical trials sponsored by Abbisko Therapeutics Co, Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill for tough tumors enters human testing Results expected Dec 2026 (estimated)
- New hope for liver cancer: targeted drug ABSK-011 enters phase 2 trial Results expected Jun 2027 (estimated)
-
New pill shows promise for rare joint tumor in Late-Stage trial
Disease control OngoingThis Phase 3 trial tests whether the drug Pimicotinib (ABSK021) can shrink tumors and improve symptoms in people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that cannot be surgically removed. About 94 adults will receive either the drug or a …
Phase 3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for liver cancer: drug combo trial launches
Disease control By invitation onlyThis phase 2 trial tests a new drug, ABSK-011, combined with the immunotherapy atezolizumab (or standard care) in 118 people with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The study aims to see if the combination is safe and can shrink tumors. Par…
Phase 2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for advanced cancer patients? early trial begins
Disease control OngoingThis early-phase study tests a new oral drug, ABSK121-NX, in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check safety and find the right dose. About 169 adults will take part, and researchers will also look for any signs th…
Phase 1 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC